Related Experiment Video
Updated: Jul 13, 2026
08:45
Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
Published on: July 17, 2020
Human protein tyrosine phosphatase 1B inhibitors: QSAR by genetic function approximation
Narsingh Sachan1, Shivajirao S Kadam, Vithal M Kulkarni
1Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune-411038, India.
Journal of Enzyme Inhibition and Medicinal Chemistry
|August 7, 2007
Summary
This study developed a quantitative structure-activity relationship (QSAR) model for formylchromone derivatives as protein tyrosine phosphatase 1B (PTP 1B) inhibitors. The model predicts PTP 1B inhibitory activity based on molecular properties, aiding in the development of new diabetes and obesity treatments.
Area of Science:
- Medicinal Chemistry
- Computational Chemistry
- Pharmacology
Background:
- Protein tyrosine phosphatase 1B (PTP 1B) is a key negative regulator of insulin receptor signaling.
- Dysregulation of PTP 1B is implicated in non-insulin dependent diabetes mellitus (NIDDM) and obesity.
- Developing specific PTP 1B inhibitors is a promising therapeutic strategy.
Purpose of the Study:
- To establish a quantitative structure-activity relationship (QSAR) for formylchromone derivatives as PTP 1B inhibitors.
- To identify key molecular descriptors influencing PTP 1B inhibitory activity.
- To provide a predictive model for designing novel PTP 1B inhibitors.
Main Methods:
- Quantitative structure-activity relationship (QSAR) analysis.
- Genetic function approximation (GFA) technique for model development.
- Utilized a training set of 29 compounds and a test set of 7 compounds for validation.
Main Results:
- Developed a QSAR model with high internal (r2=0.766) and external (r2pred=0.785) consistency.
- Identified electronic, thermodynamic, and shape-related parameters as critical for PTP 1B inhibition.
- The model demonstrated strong predictive ability for formylchromone derivatives.
Conclusions:
- The QSAR model effectively correlates formylchromone structure with PTP 1B inhibitory activity.
- This study provides valuable insights for the rational design of potent PTP 1B inhibitors.
- The findings support the potential of formylchromone derivatives in treating NIDDM and obesity.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:54Protein Kinases and Phosphatases
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:26Receptor Tyrosine Kinases
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...